Healthcare / Drug Manufacturers - Specialty & GenericBSE
$20.31
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-6.8M · quality 43.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$43M
P/E
70.0x
↑EV/EBITDA
14.6x
↑ROE
1.5%
↑Gross Margin
6.4%
↓Debt/Equity
0.43
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+62.5%
FCF CAGR
—
FCF margin
-0.9%
FCF / Net income
-2.71x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $180.4M · net income $611000.0 · FCF $-1.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $180.4M | $180.4M | $210.8M | $33.6M | $42.0M |
| Net Income | $611000.00 | $611000.00 | $358000.00 | $107996.00 | $470266.00 |
| EBITDA | $4.0M | $4.0M | $1.1M | $530442.00 | $1.0M |
| EPS | 0.29 | 0.29 | 0.17 | 0.05 | 0.22 |
| Gross Margin | 6.4% | 6.4% | 3.4% | 12.2% | 14.8% |
| Operating Margin | 0.5% | 0.5% | 0.9% | 0.4% | 1.7% |
| Net Margin | 0.3% | 0.3% | 0.2% | 0.3% | 1.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.43 | 0.43 | 0.31 | 0.10 | 0.01 |
| Current Ratio | 1.28 | 1.28 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.7M | $-1.7M | $-10.1M | $-6.8M | $-19.4M |
| Returns | |||||
| ROE | 1.5% | 1.5% | 0.9% | 0.3% | 1.1% |
| Valuation | |||||
| P/E | 70.03 | 70.03 | 257.88 | 600.00 | 118.18 |
| EV/EBITDA | 14.61 | 14.61 | 91.75 | 121.85 | 47.92 |
| P/B | 1.01 | 1.01 | 2.22 | 1.53 | 1.33 |
| Growth & Yield | |||||
| Revenue Growth | -14.5% | -14.5% | 527.4% | -20.0% | — |
| EPS Growth | 70.6% | 70.6% | 240.0% | -77.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
83.9%
EPS terminal req.
$1.80
Spread vs growth
-13.3%
5Y implied EPS CAGR
49.7%
EPS terminal req.
$2.18
Spread vs growth
20.9%
10Y implied EPS CAGR
28.3%
EPS terminal req.
$3.51
Spread vs growth
42.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-18.8%
Start / end P/E
147.1x → 70.0x
EPS bridge
0.17 → 0.29
Residual
-37.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.